Professor Kjell-Arne Rørvik at Nofima Marine (formerly Akvaforsk) believes this is an example of the fish feed of the future.
"The best way of significantly improving fish feed involves finding and utilising components that collaborate with the fish's biology so that the energy in the feed is better utilised."
Provides more energy
When salmon weigh around 100 grams and are ready to be transferred to sea cages, they are referred to as smolt. It is clear that the biology is chanllenged when the salmon smolt are transferred from fresh water to sea water.
This major readjustment means the smolt have a poor appetite and the intake of energy-rich feed is often insufficient to maintain a good immune defence. The smolt enters a period of several weeks' duration with reduced weight and increased susceptibility to sickness.
The infectious pancreatic necrosis (IPN) virus is one of the aquaculture industry's major health challenges. The disease particularly affects smolt in the first weeks after transfer to salt water.
One method to enable smolt to have sufficient energy to fight off the disease is to add bioactive fatty acids to the feed. Tetradecylthioacetic acid (TTA) increases the salmon's ability to oxidize fat to energy.
Tested on humans then salmon
TTA has been tested on humans and is known as a remedy that reduces cholesterol, improves immune defence and increases the capacity for fat oxidation.
Scientists Kjell-Arne Rørvik and Magny Thomassen conducted TTA trials on smolt. The smolt were divided into three groups with each group receiving a different feed, one of which contained small amounts of TTA.
While in the sea cages, the salmon were exposed to a natural outbreak of IPN. As a result of the outbreak, the scientists recorded clear differences between the groups of fish that had consumed different feeds (see graph).
The results showed that the fish that consumed the feed containing TTA had a mortality rate of 2.3 per cent compared to 7.8 per cent for the fish that consumed normal feed.
"To a fish farmer, a reduction like this equates to good fish welfare," says Rørvik.
"It will also be a major advancement if the industry can implement this simple step to reduce the mortality rate in the early sea phase."
This is a user-controlled innovation project part funded by the Research Council of Norway in collaboration with BioMar and Thia Medica. Before TTA may be utilised commercially, it must gain EU approval as an additive.